Rumor: AstraZeneca could be weighing Cubist buyout

The Telegraph reported on some fresh takeover rumors last night, noting new gossip that British drugmaker AstraZeneca ($AZN) is considering a buyout of Lexington, MA-based Cubist Pharmaceuticals ($CBST), which offers potential suitors immediate additional cash flow from its top-selling antibiotic for complicated skin and MRSA infections, Cubicin. The antibiotic brought in nearly $600 million in sales last year, and some analysts think the drug might be destined for blockbuster status. AstraZeneca, which has a license to the antibiotic for the Chinese market, presumably knows the group at Cubist quite well. But we'll see whether the rumor mill proves correct on this one. Report

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.